^
    Back
    Association details:
    Biomarker:PD-L1 expression
    Cancer:Triple Negative Breast Cancer
    Drug:AiRuiKa (camrelizumab) (PD1 inhibitor) +
    famitinib (SHR 1020) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Mol Cancer
    Title:

    Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial

    Published date:
    03/25/2022
    Excerpt:
    We conducted the phase II FUTURE-C-Plus trial to assess the feasibility of combining famitinib (an angiogenesis inhibitor), camrelizumab (a PD-1 monoclonal antibody) and chemotherapy in advanced immunomodulatory TNBC patients...Within 48 enrolled patients, the objective response rate was 81.3% (95% CI, 70.2-92.3), and the median progression-free survival was 13.6 months (95% CI, 8.4-18.8)...Patients with CD8 and/or PD-L1- positive tumors benefit more from this regimen. PKD1 somatic mutation indicates worse progression-free and overall survival.
    Secondary therapy:
    albumin-bound paclitaxel
    DOI:
    10.1186/s12943-022-01536-6
    Trial ID:
    FUTURE-C-PLUS
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Cancer Res
    Title:

    Famitinib with camrelizumab and nab-paclitaxel for advanced immunomodulatory triple-negative breast cancer (FUTURE-C-PLUS): an open-label, single-arm, phase 2 trial

    Published date:
    03/03/2022
    Excerpt:
    We aimed to assess the efficacy and safety of a novel combination of famitinib, camrelizumab and nab-paclitaxel in advanced immunomodulatory TNBC....Among 30 patients with immunohistochemistry, 13 (43.3%) were PD-L1-positive, and PD-L1 was associated with favorable response.
    Secondary therapy:
    albumin-bound paclitaxel
    DOI:
    10.1158/1078-0432.CCR-21-4313